WO2023007320 - LEMBOREXANT FOR USE IN METHODS OF TREATING IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND CIRCADIAN RHYTHM SLEEP DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
National phase entry:
Publication Number
WO/2023/007320
Publication Date
02.02.2023
International Application No.
PCT/IB2022/056713
International Filing Date
20.07.2022
Title **
[English]
LEMBOREXANT FOR USE IN METHODS OF TREATING IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND CIRCADIAN RHYTHM SLEEP DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
[French]
LEMBOREXANT DESTINÉ À ÊTRE UTILISÉ DANS DES PROCÉDÉS DE TRAITEMENT D'UN TROUBLE DU RYTHME SOMMEIL/RÉVEIL ET DE TROUBLES DU RYTHME CIRCADIEN ASSOCIÉS À DES MALADIES NEURODÉGÉNÉRATIVES
Applicants **
EISAI R&D MANAGEMENT CO., LTD.
6-10 Koishikawa, 4-Chome
Bunkyo-ku, Tokyo 112-8088, JP
Inventors
MOLINE, Margaret
100 Tice Blvd.
Woodcliff Lake, New Jersey 07677, US
CHENG, Jocelyn Y.
100 Tice Blvd.
Woodcliff Lake, New Jersey 07677, US
YARDLEY, Jane
European Knowledge Center, Mosquito Way
Hatfield AL 10 9SN, GB
Priority Data
63/203,512
26.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1387 | |
| EPO | Filing, Examination | 7922 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4910 |
Total: 15389 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods of treating sleep-wake rhythm disorder and related circadian rhythm sleep disorders associated with neurodegenerative diseases are disclosed.[French]
L'invention concerne des procédés de traitement d'un trouble du rythme sommeil/réveil et de troubles du rythme circadien associés à des maladies neurodégénératives.